This article is more than 5 years old. Information may no longer be current.

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma

Issue: December 2018 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, open-label dose escalation study to determine the most effective and safest dose of GD2-CAR natural killer T-cells (NKT cells; GINAKIT cells), then evaluate the effect on the tumor and length of detection in the participants' blood.